Concepta PLC Directorate Changes (6257A)

TIDMCPT

RNS Number : 6257A

Concepta PLC

28 March 2017

28 March 2017

Concepta plc

("Concepta" or the "Company")

Appointment of Non-Executive Director

Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, is pleased to announce the appointment of Neil Mesher as a Non-Executive Director, with immediate effect. This appointment further bolsters the Concepta management team's commercial healthcare credentials ahead of the launch of its myLotus fertility product into China in 2017 and Europe thereafter.

Neil has more than 25 years of global experience within the healthcare and consumer electronics industries. He is currently CEO of Philips for the UK and Ireland and is on the Board of the Association of British Healthcare Industries (ABHI), from which he led the industry's response to the NHS's "5 Year Forward View", assessing opportunities for greater integration between industry and the healthcare system. Neil is also a member of the Government's Life Science Industrial Strategy Board, representing the interests of the medical technology sector with other senior leaders from across healthcare.

In line with the Company's new Non-Executive Director appointment, Concepta also announces that Neil Herbert has stepped down from his position as non-Executive Director with immediate effect. Neil was Chairman of Frontier Resources International Plc and from February 2016 remained as a Non-executive Director during the Concepta RTO. The Board wish to thank him for his contribution with the initial transition of Concepta plc.

Erik Henau, Chief Executive of Concepta, commented: "I am delighted to welcome Neil to the Board as a Non-Executive Director. His experience and insight within the healthcare industry and consumer electronics in particular will complement our existing expertise in diagnostics and will also supplement our efforts to diversify our offering to improve users' ability to manage a range of conditions beyond our current core fertility business."

Neil Mesher, Non-Executive Director of Concepta commented: "SME's and start-ups consistently show high levels of innovation and growth, but are often under-represented in strategic initiatives to bring about improvements in the healthcare system and in turn patient outcomes. Concepta is a tremendously interesting business with the potential to bring such innovation and I look forward to adding value at company level and at a much wider country level."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Mr Neil Anthony Mesher, aged 50, holds or has held the following directorships or partnerships in the past five years:

 
Current:                                                 Previous: 
Philips UK Limited                                       Respironics Respiratory 
 Philips Electronics UK Limited                           Drug Delivery (UK) LTD 
 Association of British Healthcare Industries Limited     Profile Pharma Limited 
 Little Court Farm Residents Company Limited              Small Electrical Appliance 
                                                          Marketing Association 
 

Shareholding in the Company: none

Save as disclosed, there are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

ENDS

Enquiries:

Concepta plc

Adam Reynolds, Chairman

Tel: [phone]

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: [phone]

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: [phone]

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles / Joe Burgess / Francesca Hillier

Tel: [phone]

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017, where the revenue potential of the Chinese and EU infertility market is worth c.GBP600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUBRARBOAOUAR

(END) Dow Jones Newswires

March 28, 2017 02:02 ET (06:02 GMT)